CAMP 2025 Agenda Handout with Learning Objectives

Overall Learning Objectives:

1. **Predict the feasibility of integrating digital and molecular pathology into clinical pathology workflow.**
2. **Illustrate the implications of molecular pathology advancements into the nomenclature of oncologic entities.**
3. **Grade oncologists' perspective on predictive biomarkers in cancer care.**
4. **Inspect cutting-edge technologies and their role in advancing anatomical pathology specialty.**

Friday, April 4, 2025	
Twenty-five Percent (25%) of program time has been allotted for Interactive Learning	
1:00 – 2:00pm	Registration
2:00 – 2:05 pm	Welcome Remarks – Dr. Diana Ionescu, CAMP Chair
2:05 – 2:45 pm	Chasing Molecular Alterations in Common and Uncommon Mesenchymal Neoplasms – Dr. Jinesa Moodley (British Columbia, Canada) **As a result of attending this session the participants will be able to:** 1. Discuss the role of molecular testing in common mesenchymal neoplasms 2. Explore the utility of molecular testing in "novel" mesenchymal neoplasms
2:45 – 3:00 pm	Question & Answer Period
3:00 – 3:45 pm	Emerging Challenges and Controversies in the Nosology of Soft

	Tissue Neoplasia: Could the Phenotypic Dogma Stand the Test of Time? – Dr. Abbas Agaimy (Germany) **As a result of attending this session the participants will be able to:** **1.** To understand the historical phenotypic basis of classifying neoplastic diseases. **2.** To recognize new developments and their negative impact on cell differentiation theories. To recognize potential values of aberrant markers in recognizing entities.
3:45 – 4:00 pm	Question & Answer Period
4:00 – 4:15 pm	Coffee Break
4:15 – 5:00 pm	Updates on Molecular Testing in Melanocytic Dermatopathology – Dr. Doru Andea (New York, USA) **As a result of attending this session the participants will be able to:** 1. Explain the role of molecular diagnostics in melanocytic lesions 2. Discuss recent advances in molecular techniques for melanocytic pathology 3. Interpret molecular test results in the context of melanocytic lesion diagnosis 4. Evaluate the clinical utility and limitations of molecular testing in melanocytic tumors
5:00 – 5:15 pm	Question & Answer Period
5:15 – 6:00 pm	Getting "PIK-y" With Breast Cancer – Dr. Cheryl Mather (Alberta, Canada) **As a result of attending this session the participants will be able to:** **1.** Outline the PIK3CA-PTEN-AKT-MTOR pathway and explain how it contributes to cancer progression. **2.** Compare hotspot vs. comprehensive testing for PIK3CA, PTEN, and AKT1 alterations in breast cancer and describe benefits and limitations to each approach. **3.** Use the Alberta data to define what proportion of patients will be eligible for AKT inhibitor therapy in the setting of metastatic, hormone receptor positive, HER2 negative breast cancer.

6:00 – 6:15 pm	Question & Answer Period
6:15 pm	Closing Remarks for the Day – Dr. Diana Ionescu
6:30 pm – 8:00 pm	Welcome Reception and Visit with the Sponsors

Saturday, April 5, 2025	
Empress Ballroom	
Twenty-five Percent (25%) of program time has been allotted for Interactive Learning	
8:00 – 9:00 am	Breakfast
9:00 am	Introduction – Dr. Diana Ionescu
9:05 – 9:45 am	Implementation of Digital Pathology: the McGill University Experience – Dr. Pierre Fiset (Quebec, Canada) **As a result of attending this session the participants will be able to:** 1. Identify aspects of the Pathology workflow needed for implementation of Digital Pathology for academic workflow 2. Identify aspects of the Pathology workflow needed for implementation of Digital Pathology for clinical workflow 3. Demonstrate some open-source applications and integration of AI-tools into clinical workflow
9:45 – 10:00 am	Question & Answer Period
10:00 – 10:45 am	ctDNA as a Biomarker Source in Advanced Prostate Cancer – Dr. Alex Wyatt (British Columbia, Canada) **As a result of attending this session the participants will be able to:** **1.** Recognize the clinical scenarios where ctDNA has potential utility in prostate cancer **2.** Identify strengths and weaknesses for ctDNA cancer genotyping compared to tissue-based testing **3.** Evaluate opportunities for emerging epigenomic approaches to characterise tumour biology

10:45 – 11:00 am	Question & Answer Period
11:00 – 11:15 am	Refreshment Break
11:15 – 12:00 pm	Saved by the Bell (1): Challenging Cases Solved by Molecular Pathology – Dr. Doru Andea (New York, USA) **As a result of attending this session the participants will be able to:** **1.** Recognize the role of molecular pathology in resolving diagnostically challenging cases **2.** Review key molecular techniques used in difficult pathology cases **3.** Analyze real-world challenging cases where molecular testing influenced diagnosis and management **4.** Assess the limitations and pitfalls of molecular diagnostics in pathology
12:00 – 12:15 pm	Question & Answer Period
12:15 – 1:00 pm	Case-Based Lung Cancer Lessons – Dr. Barbara Melosky (British Columbia, Canada) **As a result of attending this session the participants will be able to:** 1. To understand the importance of the integration of pathology with genetic reports 2. To discuss the impact of new biomarker finding on patient care
1:00 – 1:15 pm	Question & Answer Period
1:15 – 2:15 pm	Lunch
2:15– 3:00 pm	Saved by the Bell (2): Challenging Cases Solved by Molecular Pathology – Dr. Abbas Agaimy (Germany) **As a result of attending this session the participants will be able to:** 1. Recognize the role of molecular pathology in resolving diagnostically challenging cases 2. Review key molecular techniques used in difficult pathology cases 3. Analyze real-world challenging cases where molecular testing influenced diagnosis and management 4. Assess the limitations and pitfalls of molecular diagnostics in pathology

3:00 – 3:15pm	Question & Answer Period
3:15 – 4:00 pm	Rapid Molecular Diagnosis of Cancer – Dr. Stephen Yip (British Columbia, Canada) **As a result of attending this session the participants will be able to:** **1.** Understand the challenges and impact of timely molecular diagnosis of cancer **2.** Appreciate the potential of the Oxford nanopore platform in facilitating diagnosis **3.** Discuss the future landscape of pathology diagnosis leveraging methylation profiling
4:00 – 4:15 pm	Question & Answer Period
4:15 – 4:30 pm	Coffee Break
4:30 – 5:15 pm	Case-Based Breast Cancer Lessons – Dr. Christine Simmons (British Columbia, Canada) **As a result of attending this session the participants will be able to:** 1. Describe the impact and relevance of identifying Her2 Low in ER+ disease 2. Describe the impact and relevance of identifying Her2 Low in TNBC disease 3. Appreciate the need to help clinicians differentiate HEr2 low from Her2 ultra low and Her2 negative status
5:15 – 5:30 pm	Reflection and Lessons Learned from the Audience
5:30 pm	Closing Remarks – Dr. Diana Ionescu